company background image
6XC1 logo

Soleno Therapeutics BST:6XC1 Stock Report

Last Price

€0.17

Market Cap

€23.0m

7D

0%

1Y

-77.4%

Updated

16 Aug, 2022

Data

Company Financials +

Soleno Therapeutics, Inc.

BST:6XC1 Stock Report

Market Cap: €23.0m

6XC1 Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. More details

6XC1 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Soleno Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Soleno Therapeutics
Historical stock prices
Current Share PriceUS$0.17
52 Week HighUS$0.77
52 Week LowUS$0.16
Beta0.24
11 Month Change0%
3 Month Changen/a
1 Year Change-77.36%
33 Year Changen/a
5 Year Change-88.30%
Change since IPO-99.33%

Recent News & Updates

Recent updates

Shareholder Returns

6XC1DE BiotechsDE Market
7D0%0.8%-0.4%
1Y-77.4%-16.7%7.1%

Return vs Industry: 6XC1 underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: 6XC1 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 6XC1's price volatile compared to industry and market?
6XC1 volatility
6XC1 Average Weekly Movementn/a
Biotechs Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6XC1 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 6XC1's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199920Anish Bhatnagarsoleno.life

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.

Soleno Therapeutics, Inc. Fundamentals Summary

How do Soleno Therapeutics's earnings and revenue compare to its market cap?
6XC1 fundamental statistics
Market cap€22.99m
Earnings (TTM)-€23.01m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6XC1 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$23.42m
Earnings-US$23.42m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.19
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 6XC1 perform over the long term?

See historical performance and comparison